<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16681">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970709</url>
  </required_header>
  <id_info>
    <org_study_id>2013-101</org_study_id>
    <nct_id>NCT01970709</nct_id>
  </id_info>
  <brief_title>Diagnosing Adverse Drug Reactions Registry</brief_title>
  <acronym>DART</acronym>
  <official_title>DART Registry: Diagnosing Adverse Drug Reactions Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renaissance RX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Renaissance RX</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter Registry is to assess whether the use of pharmacogenomic data results in a
      meaningful change in a subject's drug or dose regimen. In addition, the Registry will
      evaluate the relationship between adverse drug reactions (ADR) and genotype and assess
      resource utilization (emergency department visits and hospitalizations) associated with ADR.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <target_duration>60 Days</target_duration>
  <primary_outcome>
    <measure>Occurrence of meaningful change in drug regimen</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each subject when:
A genotype known to affect a drug the subject is taking is identified, and
The subject's treating physician makes at least one drug regimen change in concordance with the PharmD recommendations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the regimen of drugs controlled by genes of interest over the 12 months prior to enrollment and change in the regimen of drugs controlled by genes of interest over the 60 days following receipt of pharmacogenetic test results.</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ADR per month over the 12 months prior to enrollment and number of ADR per month over the 60 days following receipt of pharmacogenomic test results.</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of genome-based PharmD recommendations to alter drug or dose.</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency department visits and hospitalizations</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Emergency department visits over the 12 months prior to enrollment, emergency department visits over the 60 days following receipt of test results, hospitalizations over the 12 months prior to enrollment, and hospitalizations over the 60 days following receipt of test results.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250000</enrollment>
  <condition>Genetics of Drug Metabolism</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal swab
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female subjects over the age of 18, taking three or more medications, two of
        which are metabolized by the CYP450 pathway.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has care coordinated at the treating physician's outpatient clinic;

          -  Subject has provided written informed consent;

          -  Subject is taking at least three (3) regularly scheduled medications, excluding as
             needed (PRN) medications, over the counter medications and nutritional supplements;
             two (2) of which are known to be affected by genetic allelic variation.

          -  Subject's treating physician has a clinical suspicion that the subject is
             experiencing adverse signs or symptoms related to a prescribed medication or is not
             achieving the intended effect from the medication.

        Exclusion Criteria:

          -  Subject has a history of chronic renal dysfunction, Chronic Kidney Disease Stage 4 or
             5;

          -  Subject has a history of abnormal hepatic function within the last 2 years (INR &gt;1.2
             not attributable to anticoagulant medications, AST (aspartate aminotransferase) or
             ALT (alanine aminotransferase) &gt;1.5x normal, or suspected cirrhosis);

          -  Subject has a history of malabsorption (short gut syndrome);

          -  Subject has a history of any gastric or small bowel surgery;

          -  Subject is currently hospitalized;

          -  Subject is currently being treated with intravenous medication;

          -  Subject underwent prior pharmacogenomic testing with results reported within the last
             12 months.

        Subjects may be eligible within 60 days from the date of pharmacogenomic testing.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karthik Kasirajan</last_name>
    <email>kkasirajan@renrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophia Ly</last_name>
    <email>sly@syntactx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Edwards Lake Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andreas Maddux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holland Center for Family Health</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joshua Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boulder Medical Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Holland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Care Associates, P.A.</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ravi Mehan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Heart Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Allison Dupont, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Anesthesia Pain Specialists</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kenneth Candido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Care Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Guiler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Luling</city>
        <state>Louisiana</state>
        <zip>70070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chris Paris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Medical Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Mississippi</state>
        <zip>38732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sage Neuroscience Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Durham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwestern Internal Medicine Associates (MIMA)</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parminder Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Partners in Clinical Research</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colonial Family Practice</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Leonard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palmetto Heart</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vince Vismara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkway Cardiology Associates</name>
      <address>
        <city>Oak Ridge</city>
        <state>Tennessee</state>
        <zip>37830</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Milan Sheth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, Rajkumar C, Bernabei R, van der Cammen TJ. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older: the GerontoNet ADR risk score. Arch Intern Med. 2010 Jul 12;170(13):1142-8. doi: 10.1001/archinternmed.2010.153.</citation>
    <PMID>20625022</PMID>
  </reference>
  <reference>
    <citation>Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200-5.</citation>
    <PMID>9555760</PMID>
  </reference>
  <reference>
    <citation>Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011 Nov 24;365(21):2002-12. doi: 10.1056/NEJMsa1103053.</citation>
    <PMID>22111719</PMID>
  </reference>
  <reference>
    <citation>Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007 Jul 14;370(9582):185-91. Review.</citation>
    <PMID>17630042</PMID>
  </reference>
  <reference>
    <citation>Epstein RS, Moyer TP, Aubert RE, O Kane DJ, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol. 2010 Jun 22;55(25):2804-12. doi: 10.1016/j.jacc.2010.03.009. Epub 2010 Apr 8.</citation>
    <PMID>20381283</PMID>
  </reference>
  <reference>
    <citation>Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011 Mar 24;364(12):1144-53. doi: 10.1056/NEJMra1010600. Review.</citation>
    <PMID>21428770</PMID>
  </reference>
  <reference>
    <citation>Aronson JK. Adverse drug reactions--no farewell to harms. Br J Clin Pharmacol. 2007 Feb;63(2):131-5.</citation>
    <PMID>17274787</PMID>
  </reference>
  <reference>
    <citation>Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7;356(9237):1255-9.</citation>
    <PMID>11072960</PMID>
  </reference>
  <reference>
    <citation>Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep;84(3):326-31. Epub 2008 Feb 27. Erratum in: Clin Pharmacol Ther. 2008 Sep;84(3):430.</citation>
    <PMID>18305455</PMID>
  </reference>
  <reference>
    <citation>International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753-64. Erratum in: N Engl J Med. 2009 Oct 15;361(16):1613. Dosage error in article text.</citation>
    <PMID>19228618</PMID>
  </reference>
  <reference>
    <citation>Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010 Dec;104(6):1099-105. doi: 10.1160/TH10-07-0491. Epub 2010 Sep 30. Review.</citation>
    <PMID>20886196</PMID>
  </reference>
  <reference>
    <citation>Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010;28(1):61-74. doi: 10.2165/11318240-000000000-00000.</citation>
    <PMID>20014877</PMID>
  </reference>
  <reference>
    <citation>Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.</citation>
    <PMID>21270786</PMID>
  </reference>
  <reference>
    <citation>Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW. Adverse drug events in ambulatory care. N Engl J Med. 2003 Apr 17;348(16):1556-64.</citation>
    <PMID>12700376</PMID>
  </reference>
  <reference>
    <citation>Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011 Sep;42(9):2431-5. doi: 10.1161/STROKEAHA.111.615260. Epub 2011 Jul 28.</citation>
    <PMID>21799168</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adverse Drug Reactions</keyword>
  <keyword>Emergency Department Visits</keyword>
  <keyword>Hospitalizations</keyword>
  <keyword>Pharmacogenomic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Drug Toxicity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
